Synthesis of Tetrahydro-2H-[1, 3, 5]thiadiazine-5-(4-pyridylcarboxamido)-2-thione with antitubercular activity

Scientia Pharmaceutica

Volumn 72, Issue 1, 2004, Pages 35-41

  Sriram, D ^a   Mallika, K Jyothi ^a   Yogeeswari, P ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Antitubercular; Isoniazid

Indexed keywords

ISONIAZID DERIVATIVE; TETRAHYDRO 2H 1,3,5 THIADIAZINE 5 (4 PYRIDYLCARBOXAMIDO) 2 THIONE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; LIPOPHILICITY; MYCOBACTERIUM TUBERCULOSIS; RADIOMETRY;

EID: 1842783957     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.aut-04-04     Document Type: Article

References (16)

1. Bloom B R, Murray C J L, Tuberculosis: commentary on a reemergent killer. Science 1992; 257, 1055-64.
2. Barnes P F, Blotch A B, Davidson P T, Snider D E, Jr., Tuberculosis in patients with human immunodeficiency virus infection. N. Engl. J. Med. 1991; 324, 1644-50.
3. Sbarbaro J A, 'Multidrug'-resistant tuberculosis. It is time to focus on the private sector of medicine. Chest 1997; 111, 1149-51.
4. Fujiwara P I, Cook S V, Rutherford C M, Crawford J T, Glickman S E, Kreiswirth B N, Sachdev P S, Osahan S S, Ebrahimzadeh A, Frieden T R, A continuing survey of drug-resistant tuberculosis, New York City, April 1994. Arch. Intern. Med. 1997; 157, 531-6.
5. Schaberg T, Gloger G, Reichert B, Mauch H, Lode H, Resistant lung tuberculosis in Berlin 1987-1993. Pneumologie 1996; 50, 21-7.
6. Blair I A, Timoco R M, Brodie M J, Clarc R A, Dollery T, Timbrell J A, Beever I A, Plasma hydrazine concentrations in man after isoniazid and hydralazine administration. Hum. Toxicol. 1985; 4, 195-202.
7. th ed. Gilman A G, Rull T W, Nies A S, Taylor P. New York: Pergamon Press, 1991: 1147.
8. st ed. Volume 4, Pliska V, Testa B, Waterbeemd H. New York, Basel, Cambridge, Tokyo: VCH, Weinheim, 1996: 233.
9. Wechter W J, Johnson M A, Hall C M, Warner D T, Berger A E, Wenzel A H, Gish D T, Neil G L, ara-Cytidine acylates. Use of drug design predictors in structure-activity relationship correlation. J. Med. Chem. 1975: 18, 339-44.
10. Ryu E K, Ross R J, Matsushita T, MacCoss M, Hong C I, West C R, Phospholipid-nucleoside conjugates. 3. Syntheses and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine 5′ -monophosphate-L-1,2-dipalmitin and selected 1-beta-D-arabinofuranosylcytosine 5-diphosphate-L-1,2-diacylglycerols. J. Med. Chem. 1982; 25, 1322-9.
11. Ertan M, Tayhan A B, Yulung N, Synthesis and antimicrobial activities of some new tetrahydro-2H-1,3,5-thiadiazine-2-thione derivatives of ampicillin. Arch. Pharm. (Weinheim) 1990; 323, 605-9.
12. Aboul-Fadl T, El-Shorbagi A, New carriers for representative peptides and peptide drugs. Arch. Pharm. Pharm. Med. Chem. 1997: 330, 327-32.
13. Aboul-Fadl T, Hassanin K, Tetrahydro-2H-1,3,5-thiadiazine-5-(4-pyridylcarboxamide)-2-thione derivatives as prodrugs for isoniazid; synthesis, investigations and in vitro antituberculous activity. Pharmazie 1999: 54, 244-7.
14. Moss J, Bundgaard H, Prodrugs of peptides. 6. Bioreversible derivatives of thyrotropin-releasing hormone (TRH) with increased lipophilicity and resistance to cleavage by the TRH-specific serum enzyme. Pharm. Res. 1990: 7, 885-92.
15. th ed. Murray P R, Baron E J, Pfaller M A, Tenover F C, Yoken R H. Washington/Main: ASM Press, 1995: 1385.
16. th ed. Lorian V. Baltimore/Main: Williams & Wilkins, 1996: 127.